Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
9 articles
Newest firstBackground Although current treatment guidelines recommend against cannabinoids for Post-Traumatic Stress Disorder (PTSD), their use has increased in clinical settings despite fragmented evidence. This review critically examines the efficacy, effectiveness, and safety of cannabinoid-based interventions for PTSD. Methods We conducted a scoping review following PRISMA-ScR guidelines. Five databases were searched up…
Open article record in new tab ↗BACKGROUND: Since its initial approval in 1992, medical cannabis (MC) in Israel has undergone extensive regulatory and structural transformation. This study aims to present the most comprehensive retrospective analysis to date of the evolving MC policy framework in Israel and its impact on patient access, prescribing patterns, and treatment characteristics from 2011 to 2025. METHODS: The study included a longitudi…
Open article record in new tab ↗The use of medical cannabis (MC) to treat cancer-related symptoms is rising. However, there is a lack of long-term trials to assess the benefits and safety of MC treatment in this population. In this work, we followed up prospectively and longitudinally on the effectiveness and safety of MC treatment. Oncology patients reported on multiple symptoms before and after MC treatment initiation at one-, three-, and 6-mo…
Open article record in new tab ↗Background Although the worldwide use of medical cannabis (MC) is on the rise, there is insufficient data regarding the long-term stability of phytocannabinoids in the plant material under different storage conditions. Specifically, there is insufficient data on the effect of storage conditions on the availability of (-)-∆9-trans-tetrahydrocannabinol (THC) in vaporized cannabis. The Syqe inhaler delivers metered d…
Open article record in new tab ↗AbstractObjectiveAttaining good outcomes in the management of chronic pain remains a clinical challenge. This study aimed to investigate the relationships between – and the contribution of – pain and related conditions to the wellness of these patients.DesignA secondary analysis of database of patients with chronic pain treated with medical cannabis (MC) to carry out a one‐year prospective follow‐up study was cond…
Open article record in new tab ↗Introduction: Chronic non-cancer pain (CNCP) is one of the most prevalent indications for medical cannabis (MC) treatment globally. In this study, we investigated CNCP parameters in patients during prolonged MC treatment, and assessed the interrelation between CNCP parameters and the chemical composition of MC chemovar used. Methods: A cross-sectional questionnaire-based study was performed in one-month intervals…
Open article record in new tab ↗Objective The aim of this cross-sectional questionnaire-based study was to identify associations between the doses of cannabinoids and terpenes administered, and symptoms of attention deficit hyperactivity disorder (ADHD). Methods Participants were adult patients licensed for medical cannabis (MC) treatment who also reported a diagnosis of ADHD by a physician. Data on demographics, ADHD, sleep, and anxiety were co…
Open article record in new tab ↗Background Medical cannabis (MC) treatment for migraine is practically emerging, although sufficient clinical data are not available for this indication. This cross-sectional questionnaire-based study aimed to investigate the associations between phytocannabinoid treatment and migraine frequency. Methods Participants were migraine patients licensed for MC treatment. Data included self-reported questionnaires and M…
Open article record in new tab ↗In the last decade the use of medical cannabis (MC) for palliative cancer treatment has risen. However, the choice between products is arbitrary and most patients are using Tetrahydrocannabinol (THC)-dominant cannabis products. In this study, we aimed to assess the short-term outcomes of MC treatment prescribed by oncologists in relation to the type of cannabis they receive. A comparative analysis was used to asse…
Open article record in new tab ↗